Executive Medicine logo

Genetic Testing — What Matters and What Actually Changes Care Sydney CBD

Dr. Georgia Wyatt

Established 2004

Last updated:

a doctor in lab coat pointing at genetic markers on a digital screen

From limited use to clinically actionable — and why context still matters

Genetic testing has reached a turning point.

For years, it was either difficult to access or produced results that were not clinically useful.

That has changed.

What is different now

We now have genetic tests that can meaningfully alter how we screen, prevent and manage disease.

These are not “wellness” tests — they are clinically actionable.

In the right context, genetic information can shift both risk assessment and long-term management.

Examples of clinically useful testing

Some genetic tests have clear implications for screening and prevention:

  • BRCA — breast, ovarian, prostate and pancreatic cancer risk
  • Lynch syndrome — colorectal and related cancers
  • Familial hyperlipidaemia — early cardiovascular disease

These results can directly influence how early screening begins, how frequently it is performed, and what preventative strategies are considered.

Why the value is in what follows

The benefit of genetic testing is not simply in knowing.

It is in what happens next.

  • Earlier and more appropriate screening
  • Targeted prevention strategies
  • Detection of disease at a more treatable stage

Without a clear plan, genetic information has limited value.

Where caution is required

Genetic testing is not something to apply broadly without thought.

Some tests require careful consideration because the result may not clearly change management.

APOE is one example. It can provide insight into Alzheimer’s risk, but may also create significant psychological burden without offering a clear preventative pathway.

For that reason, it is not included in routine screening and is only offered after a detailed discussion about the implications.

The role of clinical judgement

At Executive Medicine, the focus is not on ordering more tests.

It is on choosing the right tests, interpreting them in context, and building a clear plan from the result.

If you are considering genetic testing, it is worth assessing whether the result will meaningfully influence your management.

You can explore this further through our Premium Plus Executive Health Assessment.

Dr Georgia Wyatt, CEO and Medical Director of Executive Medicine

About the Author

Dr Georgia Wyatt

CEO and Medical Director of Executive Medicine

Dr Georgia Wyatt is CEO and Medical Director of Executive Medicine, a Sydney CBD clinic established in 1985. She is a Fellow of the Royal Australian College of General Practitioners with additional training in tropical medicine and child health. Her clinical focus is on early detection, preventative care and long-term health planning, with an emphasis on structured, evidence-based assessment and continuity of care. Dr Wyatt’s approach centres on identifying meaningful risk patterns early and translating them into clear, practical strategies that support long-term health and performance.